Latest News

J&J keeps vaccine sales outlook unchanged after third-quarter miss

Economy20 minutes ago (Oct 19, 2021 15:41)

© Reuters. FILE PHOTO: Vials labelled “COVID-19 Coronavirus Vaccine” and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration

By Manas Mishra and Carl O’Donnell

(Reuters) -Johnson & Johnson on Tuesday reported lower-than- expected quarterly revenue after sales of its COVID-19 vaccine missed Wall Street estimates following a string of production setbacks.

The New Brunswick, New Jersey-based company maintained its 2021 sales goal of $2.5 billion from the vaccine, and said it recorded $766 million in sales of the shot in the first nine months of 2021 – which indicates that sales will have to more than triple in the fourth quarter to meet its forecast.

“We’re still very much committed to the $2.5 billion of revenue and the supply that is correlated to that,” Chief Financial Officer Joseph Wolk told investors on a conference call.

The drugmaker earlier this year experienced quality problems at a Baltimore manufacturing facility that produces the single-dose vaccine, resulting in wastage of millions of doses.

The J&J (NYSE:JNJ) shot, once touted an as important tool for vaccinating hard-to-reach areas, is behind its schedule for deliveries in the United States and Europe.

The vaccine has the lowest uptake in the United States at a time when rivals Moderna (NASDAQ:MRNA) Inc and Pfizer (NYSE:PFE) are signing up supply deals for booster doses in 2022 and beyond.

“It’s hard to say if J&J will meet that target or not, but with the booster guidance coming out soon, that could provide a boost to the fourth quarter,” Edwards Jones analyst Ashtyn Evans told Reuters.

The U.S. Food and Drug Administration (FDA) has yet to authorize a booster dose of the J&J vaccine, with a decision expected in the coming days.

J&J’s shares rose nearly 2% in morning trade, reversing a premarket fall, as the company raised its overall adjusted profit forecast and beat earnings estimates.

Sales in its medical devices unit rose 8% to $6.64 billion but missed analyst estimates of $6.87 billion, hurt by a resurgence in COVID-19 cases due to the Delta variant.

Excluding items, J&J earned $2.60 per share, beating expectations of $2.35 per share, according to Refinitv data.

J&J lifted its 2021 forecast for adjusted earnings per share to between $9.77 and $9.82, from its prior estimates of $9.60 to $9.70.

Overall sales of $23.34 billion missed expectations of $23.72 billion.

COVID-19 vaccine sales of $502 million missed estimates of $815 million, according to FactSet.

J&J keeps vaccine sales outlook unchanged after third-quarter miss

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

EU starts debate on budget rules amid high debt, investment needs

Previous article

MARKET WRAP: FTSE ekes out gain, Bitcoin choppy at ETF begins trading

Next article

You may also like


Leave a reply

Your email address will not be published.

More in Latest News